Cargando…

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study

Apixaban and rivaroxaban require lead-in dosing for 7 and 21 days, respectively, when treating venous thromboembolism (VTE). However, no evidence exists to support subtracting parenteral anticoagulation days from total lead-in dosing. A multicenter study was conducted, including adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alshaya, Omar A., Korayem, Ghazwa B., Al Yami, Majed S., Qudayr, Asma H., Althewaibi, Sara, Fetyani, Lolwa, Alshehri, Shaden, Alnashmi, Fai, Albasseet, Maram, Alshehri, Lina, Alhushan, Lina M., Almohammed, Omar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821121/ https://www.ncbi.nlm.nih.gov/pubmed/36615002 http://dx.doi.org/10.3390/jcm12010199

Ejemplares similares

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
por: Al Yami, Majed S., et al.
Publicado: (2023)

Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study
por: Korayem, Ghazwa B, et al.
Publicado: (2023)

Calcium Channel Blocker Toxicity: A Practical Approach
por: Alshaya, Omar A, et al.
Publicado: (2022)

Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center
por: Korayem, Ghazwa B., et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia
por: Al Yami, Majed S, et al.
Publicado: (2021)

Assessing the prevalence and characteristics of self-reported penicillin allergy in Saudi Arabian population: A nationwide cross-sectional study
por: Alowais, Shuroug A., et al.
Publicado: (2023)

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
por: Korayem, Ghazwa B., et al.
Publicado: (2022)

Voriconazole-Induced Hepatotoxicity Resolved after Switching to Amphotericin B in Fusarium dimerum Central Line-Associated Bloodstream Infection
por: Alshaya, Omar A., et al.
Publicado: (2021)

The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines
por: Alsubaie, Norah S., et al.
Publicado: (2021)

Simulation-Based Education Implementation in Pharmacy Curriculum: A Review of the Current Status
por: Korayem, Ghazwa B, et al.
Publicado: (2022)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
por: Badreldin, Hisham A, et al.
Publicado: (2020)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Apixaban/heparin/rivaroxaban: Melaena and thrombocytopenia: 2 case reports
Publicado: (2020)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Thrombolytic therapy in cardiac arrest caused by cardiac etiologies or presumed pulmonary embolism: An updated systematic review and meta‐analysis
por: Alshaya, Omar A., et al.
Publicado: (2022)

Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis
por: Alfayez, Osamah M., et al.
Publicado: (2020)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Impact of Thromboprophylaxis Intensity on Patients’ Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study
por: Almohareb, Sumaya N, et al.
Publicado: (2022)

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
por: Alkhatib, Nimer S., et al.
Publicado: (2022)

Evaluation of Apixaban in Patients With Antiphospholipid Syndrome: A Case Series and Review of Literature
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Parents' Hesitancy to Vaccinate Their 5–11-Year-Old Children Against COVID-19 in Saudi Arabia: Predictors From the Health Belief Model
por: Almalki, Ohoud S., et al.
Publicado: (2022)

Corrigendum: Parents' Hesitancy to Vaccinate Their 5–11-Year-Old Children Against COVID-19 in Saudi Arabia: Predictors From the Health Belief Model
por: Almalki, Ohoud S., et al.
Publicado: (2022)

Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis
por: Altoukhi, Renad M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nm8dd8d6s3akguvbh09tetm73d